These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

438 related articles for article (PubMed ID: 23033949)

  • 1. Signal transduction pathways of the epidermal growth factor receptor in colorectal cancer and their inhibition by small molecules.
    Efferth T
    Curr Med Chem; 2012; 19(33):5735-44. PubMed ID: 23033949
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Acquired resistance to EGFR-targeted therapies in colorectal cancer.
    Van Emburgh BO; Sartore-Bianchi A; Di Nicolantonio F; Siena S; Bardelli A
    Mol Oncol; 2014 Sep; 8(6):1084-94. PubMed ID: 24913799
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Resistance to anti-EGFR therapies in metastatic colorectal cancer: underlying mechanisms and reversal strategies.
    Zhou J; Ji Q; Li Q
    J Exp Clin Cancer Res; 2021 Oct; 40(1):328. PubMed ID: 34663410
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Multidimensional Screening Platform for Simultaneously Targeting Oncogenic KRAS and Hypoxia-Inducible Factors Pathways in Colorectal Cancer.
    Bousquet MS; Ma JJ; Ratnayake R; Havre PA; Yao J; Dang NH; Paul VJ; Carney TJ; Dang LH; Luesch H
    ACS Chem Biol; 2016 May; 11(5):1322-31. PubMed ID: 26938486
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Significance of FGF9 gene in resistance to anti-EGFR therapies targeting colorectal cancer: A subset of colorectal cancer patients with FGF9 upregulation may be resistant to anti-EGFR therapies.
    Mizukami T; Togashi Y; Naruki S; Banno E; Terashima M; de Velasco MA; Sakai K; Yoneshige A; Hayashi H; Fujita Y; Tomida S; Nakajima TE; Fujino T; Boku N; Ito A; Nakagawa K; Nishio K
    Mol Carcinog; 2017 Jan; 56(1):106-117. PubMed ID: 26916220
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Recent Advances in Targeting the EGFR Signaling Pathway for the Treatment of Metastatic Colorectal Cancer.
    Miyamoto Y; Suyama K; Baba H
    Int J Mol Sci; 2017 Apr; 18(4):. PubMed ID: 28368335
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Epidermal growth factor receptor: pathway, therapies, and pipeline.
    Goffin JR; Zbuk K
    Clin Ther; 2013 Sep; 35(9):1282-303. PubMed ID: 24054705
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Epidermal growth factor receptor (EGFR) and squamous cell carcinoma of the skin: molecular bases for EGFR-targeted therapy.
    Uribe P; Gonzalez S
    Pathol Res Pract; 2011 Jun; 207(6):337-42. PubMed ID: 21531084
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Plasticity of Resistance and Sensitivity to Anti-Epidermal Growth Factor Receptor Inhibitors in Metastatic Colorectal Cancer.
    Sartore-Bianchi A; Siena S
    Handb Exp Pharmacol; 2018; 249():145-159. PubMed ID: 28382467
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeting the EGFR signalling pathway in metastatic colorectal cancer.
    Napolitano S; Martini G; Ciardiello D; Del Tufo S; Martinelli E; Troiani T; Ciardiello F
    Lancet Gastroenterol Hepatol; 2024 Jul; 9(7):664-676. PubMed ID: 38697174
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The predictive value of KRAS, NRAS, BRAF, PIK3CA and PTEN for anti-EGFR treatment in metastatic colorectal cancer: A systematic review and meta-analysis.
    Therkildsen C; Bergmann TK; Henrichsen-Schnack T; Ladelund S; Nilbert M
    Acta Oncol; 2014 Jul; 53(7):852-64. PubMed ID: 24666267
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Predictive and prognostic factors in the complex treatment of patients with colorectal cancer.
    László L
    Magy Onkol; 2010 Dec; 54(4):383-94. PubMed ID: 21163770
    [TBL] [Abstract][Full Text] [Related]  

  • 13. PTEN expression controls cellular response to cetuximab by mediating PI3K/AKT and RAS/RAF/MAPK downstream signaling in KRAS wild-type, hormone refractory prostate cancer cells.
    Bouali S; Chrétien AS; Ramacci C; Rouyer M; Becuwe P; Merlin JL
    Oncol Rep; 2009 Mar; 21(3):731-5. PubMed ID: 19212633
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dual Inhibition of MEK and PI3K Pathway in KRAS and BRAF Mutated Colorectal Cancers.
    Temraz S; Mukherji D; Shamseddine A
    Int J Mol Sci; 2015 Sep; 16(9):22976-88. PubMed ID: 26404261
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Epidermal growth factor receptor as a therapeutic target for the treatment of colorectal cancer.
    Amador ML; Hidalgo M
    Clin Colorectal Cancer; 2004 May; 4(1):51-62. PubMed ID: 15207021
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Targeting KRAS in metastatic colorectal cancer: current strategies and emerging opportunities.
    Porru M; Pompili L; Caruso C; Biroccio A; Leonetti C
    J Exp Clin Cancer Res; 2018 Mar; 37(1):57. PubMed ID: 29534749
    [TBL] [Abstract][Full Text] [Related]  

  • 17. PAC exhibits potent anti-colon cancer properties through targeting cyclin D1 and suppressing epithelial-to-mesenchymal transition.
    Al-Qasem A; Al-Howail HA; Al-Swailem M; Al-Mazrou A; Al-Otaibi B; Al-Jammaz I; Al-Khalaf HH; Aboussekhra A
    Mol Carcinog; 2016 Mar; 55(3):233-44. PubMed ID: 25641341
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Anti-EGFR Therapy: Strategies in Head and Neck Squamous Cell Carcinoma.
    Oliveira-Silva RJ; Carolina de Carvalho A; de Souza Viana L; Carvalho AL; Reis RM
    Recent Pat Anticancer Drug Discov; 2016; 11(2):170-83. PubMed ID: 26955963
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A novel PI3K axis selective molecule exhibits potent tumor inhibition in colorectal carcinogenesis.
    Hussain A; Qazi AK; Mupparapu N; Kumar A; Mintoo MJ; Mahajan G; Sharma PR; Singh SK; Bharate SB; Zargar MA; Ahmed QN; Mondhe DM; Vishwakarma RA; Hamid A
    Mol Carcinog; 2016 Dec; 55(12):2135-2155. PubMed ID: 26764221
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Receptor tyrosine kinase-dependent PI3K activation is an escape mechanism to vertical suppression of the EGFR/RAS/MAPK pathway in KRAS-mutated human colorectal cancer cell lines.
    Vitiello PP; Cardone C; Martini G; Ciardiello D; Belli V; Matrone N; Barra G; Napolitano S; Della Corte C; Turano M; Furia M; Troiani T; Morgillo F; De Vita F; Ciardiello F; Martinelli E
    J Exp Clin Cancer Res; 2019 Jan; 38(1):41. PubMed ID: 30691487
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.